Logo image of RDNT

RADNET INC (RDNT) Stock Fundamental Analysis

NASDAQ:RDNT - Nasdaq - US7504911022 - Common Stock - Currency: USD

65.94  +2.64 (+4.17%)

After market: 65.94 0 (0%)

Fundamental Rating

4

Overall RDNT gets a fundamental rating of 4 out of 10. We evaluated RDNT against 109 industry peers in the Health Care Providers & Services industry. RDNT has only an average score on both its financial health and profitability. RDNT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

RDNT had positive earnings in the past year.
RDNT had a positive operating cash flow in the past year.
RDNT had positive earnings in 4 of the past 5 years.
Each year in the past 5 years RDNT had a positive operating cash flow.
RDNT Yearly Net Income VS EBIT VS OCF VS FCFRDNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

1.2 Ratios

RDNT has a Return On Assets of -0.13%. This is comparable to the rest of the industry: RDNT outperforms 55.56% of its industry peers.
The Return On Equity of RDNT (-0.49%) is comparable to the rest of the industry.
RDNT has a Return On Invested Capital of 3.14%. This is comparable to the rest of the industry: RDNT outperforms 49.07% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for RDNT is below the industry average of 8.15%.
Industry RankSector Rank
ROA -0.13%
ROE -0.49%
ROIC 3.14%
ROA(3y)0.58%
ROA(5y)0.36%
ROE(3y)4.83%
ROE(5y)3.06%
ROIC(3y)3.25%
ROIC(5y)3.04%
RDNT Yearly ROA, ROE, ROICRDNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 20

1.3 Margins

In the last couple of years the Profit Margin of RDNT has declined.
RDNT has a Operating Margin of 6.36%. This is in the better half of the industry: RDNT outperforms 69.44% of its industry peers.
In the last couple of years the Operating Margin of RDNT has grown nicely.
RDNT has a Gross Margin of 23.38%. This is comparable to the rest of the industry: RDNT outperforms 48.15% of its industry peers.
In the last couple of years the Gross Margin of RDNT has remained more or less at the same level.
Industry RankSector Rank
OM 6.36%
PM (TTM) N/A
GM 23.38%
OM growth 3Y49.86%
OM growth 5Y11%
PM growth 3YN/A
PM growth 5Y-43.61%
GM growth 3Y2.03%
GM growth 5Y0.93%
RDNT Yearly Profit, Operating, Gross MarginsRDNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 10 15 20

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RDNT is destroying value.
RDNT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RDNT has more shares outstanding
The debt/assets ratio for RDNT has been reduced compared to a year ago.
RDNT Yearly Shares OutstandingRDNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
RDNT Yearly Total Debt VS Total AssetsRDNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

RDNT has an Altman-Z score of 2.00. This is not the best score and indicates that RDNT is in the grey zone with still only limited risk for bankruptcy at the moment.
RDNT has a Altman-Z score of 2.00. This is comparable to the rest of the industry: RDNT outperforms 50.93% of its industry peers.
RDNT has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as RDNT would need 10.83 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 10.83, RDNT is in line with its industry, outperforming 58.33% of the companies in the same industry.
A Debt/Equity ratio of 1.11 is on the high side and indicates that RDNT has dependencies on debt financing.
RDNT has a Debt to Equity ratio of 1.11. This is in the lower half of the industry: RDNT underperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 10.83
Altman-Z 2
ROIC/WACC0.36
WACC8.71%
RDNT Yearly LT Debt VS Equity VS FCFRDNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.3 Liquidity

RDNT has a Current Ratio of 2.16. This indicates that RDNT is financially healthy and has no problem in meeting its short term obligations.
RDNT has a Current ratio of 2.16. This is in the better half of the industry: RDNT outperforms 75.00% of its industry peers.
RDNT has a Quick Ratio of 2.16. This indicates that RDNT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.16, RDNT is doing good in the industry, outperforming 75.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
RDNT Yearly Current Assets VS Current LiabilitesRDNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

RDNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.59%, which is quite impressive.
The Earnings Per Share has been growing slightly by 2.73% on average over the past years.
RDNT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.20%.
RDNT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)36.59%
EPS 3YN/A
EPS 5Y2.73%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)12.2%
Revenue growth 3Y14.68%
Revenue growth 5Y10.64%
Sales Q2Q%14.72%

3.2 Future

Based on estimates for the next years, RDNT will show a very strong growth in Earnings Per Share. The EPS will grow by 24.68% on average per year.
RDNT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.06% yearly.
EPS Next Y33.96%
EPS Next 2Y22.87%
EPS Next 3Y24.68%
EPS Next 5YN/A
Revenue Next Year13.31%
Revenue Next 2Y11.05%
Revenue Next 3Y10.06%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RDNT Yearly Revenue VS EstimatesRDNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B
RDNT Yearly EPS VS EstimatesRDNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 0.6 0.8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

RDNT is valuated quite expensively with a Price/Earnings ratio of 117.75.
RDNT's Price/Earnings ratio is in line with the industry average.
RDNT is valuated expensively when we compare the Price/Earnings ratio to 28.42, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 87.36, the valuation of RDNT can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RDNT is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of RDNT to the average of the S&P500 Index (24.39), we can say RDNT is valued expensively.
Industry RankSector Rank
PE 117.75
Fwd PE 87.36
RDNT Price Earnings VS Forward Price EarningsRDNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

RDNT's Enterprise Value to EBITDA is on the same level as the industry average.
RDNT's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. RDNT is cheaper than 61.11% of the companies in the same industry.
Industry RankSector Rank
P/FCF 51.82
EV/EBITDA 20.04
RDNT Per share dataRDNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RDNT does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as RDNT's earnings are expected to grow with 24.68% in the coming years.
PEG (NY)3.47
PEG (5Y)43.13
EPS Next 2Y22.87%
EPS Next 3Y24.68%

More info and screens

0

5. Dividend

5.1 Amount

RDNT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RADNET INC

NASDAQ:RDNT (1/28/2025, 8:00:39 PM)

After market: 65.94 0 (0%)

65.94

+2.64 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-10 2024-11-10/amc
Earnings (Next)N/A N/A
Inst Owners85.36%
Inst Owner Change-0.03%
Ins Owners11.96%
Ins Owner Change4.97%
Market Cap4.88B
Analysts85
Price Target91.97 (39.48%)
Short Float %6.07%
Short Ratio7.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.15%
Min EPS beat(2)-12.7%
Max EPS beat(2)-5.6%
EPS beat(4)2
Avg EPS beat(4)320.19%
Min EPS beat(4)-12.7%
Max EPS beat(4)1272.55%
EPS beat(8)4
Avg EPS beat(8)189.17%
EPS beat(12)5
Avg EPS beat(12)-250.87%
EPS beat(16)8
Avg EPS beat(16)-169.61%
Revenue beat(2)2
Avg Revenue beat(2)3.01%
Min Revenue beat(2)2.78%
Max Revenue beat(2)3.25%
Revenue beat(4)4
Avg Revenue beat(4)1.72%
Min Revenue beat(4)0.36%
Max Revenue beat(4)3.25%
Revenue beat(8)8
Avg Revenue beat(8)2.54%
Revenue beat(12)9
Avg Revenue beat(12)1.12%
Revenue beat(16)12
Avg Revenue beat(16)0.94%
PT rev (1m)1.12%
PT rev (3m)16.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)1.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.34%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE 117.75
Fwd PE 87.36
P/S 2.75
P/FCF 51.82
P/OCF 17.47
P/B 5.45
P/tB 49.29
EV/EBITDA 20.04
EPS(TTM)0.56
EY0.85%
EPS(NY)0.75
Fwd EY1.14%
FCF(TTM)1.27
FCFY1.93%
OCF(TTM)3.77
OCFY5.72%
SpS23.95
BVpS12.09
TBVpS1.34
PEG (NY)3.47
PEG (5Y)43.13
Profitability
Industry RankSector Rank
ROA -0.13%
ROE -0.49%
ROCE 4.02%
ROIC 3.14%
ROICexc 4.29%
ROICexgc 7%
OM 6.36%
PM (TTM) N/A
GM 23.38%
FCFM 5.31%
ROA(3y)0.58%
ROA(5y)0.36%
ROE(3y)4.83%
ROE(5y)3.06%
ROIC(3y)3.25%
ROIC(5y)3.04%
ROICexc(3y)3.63%
ROICexc(5y)3.31%
ROICexgc(3y)5.98%
ROICexgc(5y)5.43%
ROCE(3y)4.16%
ROCE(5y)3.89%
ROICexcg growth 3Y50.2%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y50.64%
ROICexc growth 5Y4.68%
OM growth 3Y49.86%
OM growth 5Y11%
PM growth 3YN/A
PM growth 5Y-43.61%
GM growth 3Y2.03%
GM growth 5Y0.93%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 10.83
Debt/EBITDA 4.03
Cap/Depr 137.73%
Cap/Sales 10.45%
Interest Coverage 1.99
Cash Conversion 113.01%
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z 2
F-Score5
WACC8.71%
ROIC/WACC0.36
Cap/Depr(3y)129.51%
Cap/Depr(5y)117.82%
Cap/Sales(3y)10.05%
Cap/Sales(5y)9.07%
Profit Quality(3y)577.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.59%
EPS 3YN/A
EPS 5Y2.73%
EPS Q2Q%-7.14%
EPS Next Y33.96%
EPS Next 2Y22.87%
EPS Next 3Y24.68%
EPS Next 5YN/A
Revenue 1Y (TTM)12.2%
Revenue growth 3Y14.68%
Revenue growth 5Y10.64%
Sales Q2Q%14.72%
Revenue Next Year13.31%
Revenue Next 2Y11.05%
Revenue Next 3Y10.06%
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3Y71.86%
EBIT growth 5Y22.81%
EBIT Next Year183.79%
EBIT Next 3Y51.82%
EBIT Next 5YN/A
FCF growth 1Y948.59%
FCF growth 3Y-31.81%
FCF growth 5Y-0.15%
OCF growth 1Y96.8%
OCF growth 3Y-1.88%
OCF growth 5Y13.59%